Funding support and drug supply were provided by F. Hoffmann La Roche Ltd and Celgene Corporation, Independent Data Monitoring Committee (André Bosly, Catherine Sebban, and Natacha Heutte); and all the investigators ,
A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory diffuse large B-cell lymphoma, Consultant: Janssen, Keocyt et Sanofi; FM: Advisory Board, vol.23, pp.4127-4164, 2017. ,
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell nonHodgkin's lymphoma, Ann Oncol, vol.22, pp.1622-1629, 2011. ,
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial, Lancet Oncol, vol.17, pp.559-567, 2016. ,
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma, Br J Haematol, vol.180, pp.224-259, 2018. ,
Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study, J Clin Oncol, vol.31, pp.2912-2921, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01704593
Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance), J Clin Oncol, vol.33, pp.3635-3675, 2015. ,
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance), Ann Oncol J Eur Soc Med Oncol, vol.28, pp.2806-2818, 2017. ,
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial, Lancet Oncol, issue.12, pp.70200-70200, 2012. ,
Lenalidomide plus rituximab as initial treatment for mantlecell lymphoma, N Engl J Med, vol.373, pp.1835-1879, 2015. ,
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial, Clin Lymphoma Myeloma Leuk, 2011. ,
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large Bcell lymphoma, Leuk Lymphoma, 2014. ,
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, Leukemia, 2013. ,
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab, Haematologica, vol.101, pp.385-391, 2016. ,
An open-label, phase Ib study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma, Blood, 2018. ,
, J Clin Oncol, p.10561185
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study, Blood, vol.130, pp.1800-1808, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01829026
Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma, J Clin Oncol, vol.35, 2017. ,